Research Topics
| Ken FujiokaSummaryAffiliation: Scripps Clinic Country: USA Publications
| Collaborators
|
Detail Information
Publications
Benefits of moderate weight loss in patients with type 2 diabetesKen Fujioka
Department of Diabetes and Endocrine, Scripps Clinic, San Diego, CA, USA
Diabetes Obes Metab 12:186-94. 2010..The current data support a continued focus on weight loss, including moderate weight loss, as a key component of good care for overweight patients with type 2 diabetes...
Follow-up of nutritional and metabolic problems after bariatric surgeryKen Fujioka
Director of Nutrition and Metabolic Research, Scripps Clinic, Suite 317, 12395 El Camino Real, San Diego, CA 92130, USA
Diabetes Care 28:481-4. 2005..At the end of this report, a short section will be devoted to the problems associated with the malabsorptive procedures...- The effects of grapefruit on weight and insulin resistance: relationship to the metabolic syndromeKen Fujioka
Division of Endocrinology, Department of Nutrition and Metabolic Research, Scripps Clinic, La Jolla, California 92130, USA
J Med Food 9:49-54. 2006..Insulin resistance was improved with fresh grapefruit. Although the mechanism of this weight loss is unknown it would appear reasonable to include grapefruit in a weight reduction diet... - Office-based management of obesityKen Fujioka
Scripps Clinic Division of Diabetes and Endocrinology, San Diego, CA, USA
Mt Sinai J Med 77:466-71. 2010..Along with this new information will come novel treatment options. It is predicted that many of the barriers preventing appropriate management of obesity will diminish as further knowledge and treatment options become available... - Pharmacologic treatment options for obesity: current and potential medicationsKen Fujioka
Center for Weight Management, Scripps Clinic, San Diego, CA 92130, USA
Nutr Clin Pract 22:50-4. 2007..Currently available therapies are safe when used appropriately. New treatments with novel mechanisms of action are likely to be available in the future... - Metabolic syndrome treatment strategiesKen Fujioka
Nutrition and Metabolism Research Center, Scripps Clinic-Del Mar, San Diego, California 92130, USA
Pharmacotherapy 26:222S-226S. 2006..In addition, two drugs-sibutramine and rimonabant-have been evaluated and produced promising outcomes in the overall management of high-risk patients with metabolic syndrome... - Management of obesity as a chronic disease: nonpharmacologic, pharmacologic, and surgical optionsKen Fujioka
Nutrition and Metabolic Research Center, Scripps Clinic, San Diego, California 92130, USA
Obes Res 10:116S-123S. 2002..Several other drugs currently approved for other uses show promise in their ability to cause weight loss. Surgical options should be reserved for severely obese patients with significant medical comorbidities or physical conditions... - Do gastric bypass patient characteristics, behavior, and health differ depending upon how successful weight loss is defined?Karen J Coleman
Research and Evaluation, Southern California Permanente Medical Group, 100 S Los Robles, 2nd Floor, Pasadena, CA, USA
Obes Surg 20:1385-92. 2010..Future research should be done to examine how patient health and behavior predicts differing definitions of weight loss success... - Evaluating preoperative weight loss, binge eating disorder, and sexual abuse history on Roux-en-Y gastric bypass outcomeKen Fujioka
Department of Nutrition and Metabolic Research Center, Scripps Green Clinic, La Jolla, California, USA
Surg Obes Relat Dis 4:137-43. 2008..We examined preoperative weight loss, binge eating disorder (BED), and sexual abuse history and the interactions of these predictors to determine whether a cautionary approach to Roux-en-Y gastric bypass is warranted... - Nutrition and metabolic complications after bariatric surgery and their treatmentKen Fujioka
Department of Medicine, Scripps Clinic, La Jolla, California, USA
JPEN J Parenter Enteral Nutr 35:52S-9S. 2011..In this article, the authors describe nutrition problems that may be present and potentially affect the course of a hospitalized and/or critically ill patient who has previously undergone a bariatric operation... - Naltrexone for the treatment of obesity: review and updateMichael William Lee
Scripps Clinic Center for Weight Management, 12395 El Camino Real, Suite 317, San Diego, CA 92130, USA
Expert Opin Pharmacother 10:1841-5. 2009..While the opioid receptor antagonist naltrexone is associated with minimal weight loss as monotherapy, it does have potential utility in the treatment of obesity when combined with the pro-opiomelanocortin activator bupropion... - Obesity epidemic: what treatments work and whom do you treat?Ken Fujioka
Nutrition and Metabolic Research, Scripps Clinic, San Diego, Calif, USA
Manag Care 15:21-4. 2006 - Vomiting from multivitamins: a potential drug interactionFrank Greenway
Pennington Biomedical Research Center, Baton Rouge, LA 70808, USA
Am J Ther 18:453-7. 2011..This experience demonstrates that adding dietary herbal supplements to multivitamins may be associated with adverse interactions with prescription drugs... - Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunctionKen Fujioka
Center for Weight Management, Scripps Clinic, Department of Endocrinology and Diabetes, San Diego, CA, USA
JAAPA . 2007..Both classes of agent have shown promise, with potential not only to normalize fasting and postprandial glucose levels but also to improve beta-cell functioning and mass... - Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulationKen Fujioka
Nutrition and Metabolic Research Center, Scripps Clinic Del Mar, San Diego, California 92310, USA
Clin Ther 25:515-29. 2003..This newer formulation may enhance patient compliance with oral therapy and improve long-term control of diabetes compared with the conventional immediate-release formulation of metformin (MIR)... - Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation studyLouis Aronne
Weill Cornell Medical College, New York, NY 10021, USA
J Clin Endocrinol Metab 92:2977-83. 2007..In previous 1-yr trials, treatment with pramlintide (120 microg), an analog of the beta-cell hormone amylin, induced sustained reductions in A1C and body weight in insulin-using subjects with type 2 diabetes... - Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adultsNgozi Erondu
Merck and Co, Inc, 126 E. Lincoln Avenue, Rahway, New Jersey 07065
Cell Metab 4:275-82. 2006..These observations provide the first clinical insight into the human NPY-energy homeostatic pathway and suggest that solely targeting the NPY5R in future drug development programs is unlikely to produce therapeutic efficacy... - Effects of sibutramine treatment in obese adolescents: a randomized trialRobert I Berkowitz
The Behavioral Health Center, The Children s Hospital of Philadelphia and the University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
Ann Intern Med 145:81-90. 2006..Increased prevalence of adolescent obesity requires effective treatment options beyond behavior therapy... - Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trialJames W Anderson
Department of Internal Medicine, Veterans Affairs Medical Center, University of Kentucky, Lexington, Kentucky, USA
Obes Res 10:633-41. 2002..To critically examine the efficacy of bupropion SR for weight loss... - Executive summary of the recommendations of the American Association of Clinical Endocrinologists, the Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, Jeffrey I Mechanick
Endocr Pract 14:318-36. 2008